Agentic AI Powers U.S. Healthcare Stocks
Agentic AI Powers U.S. Healthcare Stocks
Alex SiroisMon, May 18, 2026 at 12:19 AM UTC
0
William Potter / Shutterstock.comQuick Read -
SoundHound AI (SOUN) posted Q1 2026 revenue of $44.2M, up 52% year over year, with core automotive and IoT organic revenue up 88%, and projects $350M-$400M in 2027 revenue once the LivePerson deal closes. Evolent Health (EVH) reaffirmed $2.4B-$2.6B in 2026 revenue with roughly 30% growth expected, with 14 of 16 analysts rating shares Buy or Strong Buy and a $5.43 consensus price target. C3.ai (AI) reported Q3 FY2026 revenue of $53.3M, down 46.1% year over year, but federal bookings jumped 134% with expected annual operating expense savings of $135M.
Healthcare systems are deploying agentic AI to reduce labor costs, creating demand for low-cost automation platforms, and these three companies are capturing that opportunity at depressed valuations despite distinct execution risks tied to margin pressure, contract performance, and restructuring outcomes.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and C3.ai wasn't one of them. Get them here FREE.
Healthcare payrolls keep climbing, and hospital systems, payers, and clinics are now openly treating agentic AI as the cheapest unit of labor on the market. Stocks trading under $20 with credible agentic AI products pointed at this cost problem are scarce, which is why a small group of names is drawing fresh attention from investors hunting for asymmetric setups in a sector where every basis point of margin matters.
With that in mind, here are three stocks trading under $20 that sit squarely at the intersection of agentic AI and healthcare, with the data to back up a closer look.
SoundHound AI (NASDAQ: SOUN)
SoundHound AI (NASDAQ:SOUN) builds voice and agentic AI software used by automakers, restaurants, banks, and healthcare providers to automate customer-facing conversations. Shares trade at $8.88, well inside the $20 ceiling and giving retail investors a low-dollar entry into an enterprise voice AI platform with a roughly $3.5 billion market cap.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and C3.ai wasn't one of them.Get them here FREE.
Q1 2026 revenue rose 52% year over year to $44.20 million, with core automotive and IoT organic revenue up 88% and a sixth consecutive EPS beat at -$0.06. Management reaffirmed $225 million to $260 million in 2026 revenue and projects at least $350 million to $400 million in 2027 once the LivePerson deal closes.
The bull case is straightforward. CEO Keyvan Mohajer said the launch of OASYS, a self-learning agentic AI platform, plus LivePerson will bring "the world's first self-learning agentic AI platform to one of the most robust enterprise footprints in the entire conversational AI sector." That includes healthcare clients like Primary Health Solutions and Allina Health. The risk is real, though: operating cash burn was -$26.3 million in Q1, and integration of LivePerson could pressure margins. For investors comfortable with that profile, SOUN remains the cleanest agentic AI growth story in the group.
Evolent Health (NYSE: EVH)
Evolent Health (NYSE:EVH) is a specialty care management firm using AI and machine learning models to handle oncology, cardiology, and musculoskeletal authorizations for health plans. At $4.18, the stock sits near the low end of its $2.095 to $12.06 52-week range, with a $470 million market cap.
Advertisement
Q1 2026 revenue came in at $496.25 million, missing expectations, but adjusted EPS of -$0.02 beat the -$0.0467 consensus by 57.17%. Management reaffirmed $2.40 billion to $2.60 billion in 2026 revenue, implying roughly 30% growth, with two Q3 launches including a national payer expansion expected to generate over $200 million in annual revenue. The analyst consensus price target ranges from approximately $6.12 to $8.00 depending on the source, with the majority of covering analysts rating shares Buy or Strong Buy.
CEO Seth Blackley framed the AI thesis directly, saying the company is "addressing the big opportunity we have with AI." The risk: the Performance Suite medical expense ratio jumped to 93.3% from 84.0% a year ago, squeezing margins. Still, EVH offers the purest healthcare AI exposure on this list at a depressed valuation.
C3.ai (NYSE: AI)
C3.ai (NYSE:AI) sells enterprise AI applications, including an agentic AI platform deployed at the Department of Health and Human Services and Bristol Myers Squibb. Shares trade at $9.87, down 57.95% over the past year.
Q3 FY2026 revenue dropped 46.1% year over year to $53.26 million, missing expectations by 29.59%, and GAAP gross margin collapsed to 17% from 59% a year earlier. Management slashed full-year guidance to $246.7 million to $250.7 million and cut 26% of headcount. The analyst consensus price target sits at $8.82, below the current price, with 6 sell ratings against 1 buy.
The contrarian case rests on roughly $135 million in expected annual operating expense savings and federal bookings up 134% year over year. The bear case is louder: cash fell 28.98% to $88.8 million, free cash flow was -$56.2 million, and the restructuring triggered an investor fraud investigation. C3.ai screens as the highest-risk turnaround in this group, suitable only for investors who want explicit exposure to a recovery story still in its earliest innings.
A share price under $20 is a starting point for screening, not a thesis on its own. Each of these names carries distinct execution risk tied to healthcare contracts, margin pressure, or restructuring outcomes, so readers should run their own due diligence on guidance, cash runway, and competitive positioning before acting on any agentic AI healthcare story.
The analyst who called NVIDIA in 2010 just named his top 10 AI stocks
This analyst's 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE.
Source: “AOL Money”
